PainReform says IVR rates of PRF-110 superior for post-surgical pain products

PainReform announces results from new studies demonstrating the superior in-vitro release, IVR, rates of PRF-110 compared to the industry leader for topical post-surgical pain management products. “These findings underscore PainReform’s commitment to advancing non-opiate pain relief options and mark a significant milestone…These results are particularly noteworthy as they not only provide support for PRF-110’s superior efficacy but also its potential to significantly extend the duration of pain relief. By ensuring a more consistent and prolonged analgesic effect, PRF-110 aims to reduce the dependency on opiates for post-surgical pain management, addressing a critical need in the healthcare system for safer, more effective pain management strategies. Ilan Hadar, Chief Executive Officer of PainReform, expressed his enthusiasm about the findings: “These IVR study results are a testament to the innovative approach we’re taking at PainReform to combat post-surgical pain. By focusing on extended drug release technology, we believe PRF-110 is poised to set a new standard in topical pain management that prioritizes patient safety and efficacy. We believe that this breakthrough will not only benefit patients by providing longer-lasting relief but also significantly impact the global effort to reduce opiate use.”